|
GETUG 14
|
GETUG 15
|
GETUG 16
|
GETUG 17
|
Total*
|
---|
MDC team’s decisions (1) | 17 (5.9%) | 0 | 7 (2.4%) | 2 (0.7%) | 26 (9.1%) |
CRA’s decisions (2) | 59 (20.6%) | 8 (2.8%) | 13 (4.5%) | 3 (1.0%) | 83 (29.0%) |
PI’s decisions (3) | 30 (10.5%) | 0 | 6 (2.1%) | 1 (0.3%) | 37 (12.9%) |
- *McNemar’s chi-squared test: (1) versus (2) P <10−3; (1) versus (3) P = 0.022; (2) versus (3) P <10−3.
- (1) Decisions of the physicians during the multidisciplinary cancer (MDC) meetings; (2) Decisions of a clinical research assistant (CRA) after the systematic review of the MDC reports; (3) Final decisions after the principal investigator (PI) corrected the discrepancies between the MDC team’s and the CRA’s decisions.